Immunotherapy for the Treatment of Cancer

Targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma and more with highly potent biopharmaceutical drugs designed for targeted therapy.

View Product Pipeline


GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.


Latest News

GT Biopharma, Inc. Announces Reverse Stock Spilt As Part of Oxis-Georgetown Planned Merger
Aug 21, 2017 • 12:00 EDT | Read More

GT Biopharma, Inc. (Oxis) Announces Corporate Update Conference Call With Incoming CEO Dr. Kathleen Clarence-Smith and Chairman Anthony Cataldo
Aug 7, 2017 • 8:00 EDT | Read More


GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range